Literature DB >> 18639333

The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion.

Yaokai Gan1, Kerong Dai, Pu Zhang, Tingting Tang, Zhenan Zhu, Jianxi Lu.   

Abstract

Cytotherapy for bone regeneration has not been widely used clinically. A new method based on enriched bone-marrow-derived mesenchymal stem cells (MSCs) combined with porous beta-tricalcium phosphate (beta-TCP) was used for posterior spinal fusion in 41 patients. The aim of the present study was to assess the clinical feasibility of peri-operative bone marrow stem cell enrichment and their combination with tricalcium phosphate. About 252 ml marrow per patient was harvested from bilateral iliac crest, the enriched MSCs were produced by a cell processor peri-operatively, then combined with porous beta-TCP granules by a negative pressure and a short-time incubation in the meantime of conventional operation, which were finally implanted back into the patient. About 45 ml enriched MSC suspension was collected, and 78+/-16% of MSCs were recovered. By enrichment technique, the number of colony-forming units which expressed alkaline phosphatase (CFUs-ALP+, to estimate the prevalence of MSCs) was increased 4.3 times; the increasing folds of bone marrow nucleated cells (NCs) and MSCs had a positive correlation. The natural log (ln) of MSC number declined with age, and also, the MSC number of younger subjects (< or =40 years) was more than that of older ones (>40 years), but none for NCs. The number of NCs and MSCs was not different significantly between men and women. However, the patients with thoracolumbar fracture (TLF) had significantly more MSCs than those with degenerative disc disease (DDD), but not for NCs. On the other hand, enriched MSCs could adhere to the wall of porous beta-TCP within 2h combination, and proliferate well during culture in vitro. After 34.5 months, 95.1% cases had good spinal fusion results. None of the samples before grafting was positive in bacterial culture. Only four patients had a little exudation or moderate swelling in their wounds, and recovered with conservative treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639333     DOI: 10.1016/j.biomaterials.2008.06.026

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  76 in total

Review 1.  Bone regeneration by stem cell and tissue engineering in oral and maxillofacial region.

Authors:  Zhiyuan Zhang
Journal:  Front Med       Date:  2011-12-27       Impact factor: 4.592

2.  Bone regeneration with mesenchymal stem cells.

Authors:  Elizaveta Kon; Giuseppe Filardo; Alice Roffi; Alessandro Di Martino; Mohammad Hamdan; Laura De Pasqual; Maria Letizia Merli; Maurilio Marcacci
Journal:  Clin Cases Miner Bone Metab       Date:  2012-05-29

3.  Uncultured marrow mononuclear cells delivered within fibrin glue hydrogels to porous scaffolds enhance bone regeneration within critical-sized rat cranial defects.

Authors:  James D Kretlow; Patrick P Spicer; John A Jansen; Charles A Vacanti; F Kurtis Kasper; Antonios G Mikos
Journal:  Tissue Eng Part A       Date:  2010-10-12       Impact factor: 3.845

Review 4.  An update on bone substitutes for spinal fusion.

Authors:  Masashi Miyazaki; Hiroshi Tsumura; Jeffrey C Wang; Ahmet Alanay
Journal:  Eur Spine J       Date:  2009-03-12       Impact factor: 3.134

5.  Mesenchymal stem cells derived from vertebrae (vMSCs) show best biological properties.

Authors:  Giovanni Barbanti Brodano; Silvia Terzi; Luisa Trombi; Cristiana Griffoni; Mauro Valtieri; Stefano Boriani; Maria Cristina Magli
Journal:  Eur Spine J       Date:  2013-09-24       Impact factor: 3.134

Review 6.  The possible use of stem cells in regenerative medicine: dream or reality?

Authors:  Sabrina Ehnert; Matthias Glanemann; Andreas Schmitt; Stephan Vogt; Naama Shanny; Natascha C Nussler; Ulrich Stöckle; Andreas Nussler
Journal:  Langenbecks Arch Surg       Date:  2009-07-31       Impact factor: 3.445

Review 7.  [Bone tissue engineering in clinical application : assessment of the current situation].

Authors:  P Bernstein; M Bornhäuser; K-P Günther; M Stiehler
Journal:  Orthopade       Date:  2009-11       Impact factor: 1.087

Review 8.  [Cell therapy in bone-healing disorders].

Authors:  M Jäger; P Hernigou; C Zilkens; M Herten; J Fischer; R Krauspe
Journal:  Orthopade       Date:  2010-04       Impact factor: 1.087

9.  Cell therapy for bone repair: narrowing the gap between vision and practice.

Authors:  J P Stegemann; S Verrier; F Gebhard; M W Laschke; I Martin; H Simpson; T Miclau
Journal:  Eur Cell Mater       Date:  2014-05-06       Impact factor: 3.942

10.  Clinical application of human mesenchymal stromal cells for bone tissue engineering.

Authors:  Anindita Chatterjea; Gert Meijer; Clemens van Blitterswijk; Jan de Boer
Journal:  Stem Cells Int       Date:  2010-11-11       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.